A father's age adds about two new mutations a year to the sperm he passes on

Paternal age has a measurable biological signature: sperm accumulates roughly two additional new mutations for every year of the father's age, and the total roughly doubles every 16.5 years. The downstream effects on a pregnancy and a child are real but small in absolute terms, and the largest study of them — 40 million US births — found the population-level impact modest, mostly because older fathers are still relatively uncommon.

The genetic finding

The mutation result comes from whole-genome sequencing of 78 Icelandic parent-offspring trios at high coverage [s1]. With an average father's age of 29.7, the average de novo mutation rate was 1.20 × 10⁻⁸ per nucleotide per generation [s1].

The striking part was what explained the variation. Diversity in the single-nucleotide mutation rate was dominated by the father's age at conception, with an increase of about two mutations per year [s1]. An exponential model estimated paternal mutations doubling every 16.5 years [s1]. After accounting for random Poisson variation, the father's age explained nearly all of the remaining variation in de novo mutation counts [s1]. The paper's own framing is that this sheds light on the importance of paternal age for the risk of conditions such as schizophrenia and autism [s1].

Two points about what that does and does not establish. It is a direct measurement of mutation accumulation, not an estimate of disease risk — the study counted mutations in 78 families, and the link to any specific condition is inference. And the mechanism is biologically straightforward: sperm-producing cells keep dividing throughout a man's life, and each division is an opportunity for a copying error, whereas a woman's eggs do not replicate in the same way.

What shows up in births

The largest study of perinatal outcomes by paternal age is a retrospective cohort of 40,529,905 documented live births in the United States between 2007 and 2016 [s2]. Its primary perinatal outcomes were gestational age, birth weight, five-minute Apgar score, neonatal intensive care admission, need for postpartum antibiotics and seizures; the maternal outcomes were gestational diabetes and pre-eclampsia [s2].

After adjustment for maternal age, infants born to fathers aged 45 or older had 14% higher odds of premature birth than infants of fathers aged 25 to 34 (odds ratio 1.14, 95% CI 1.13 to 1.15) [s2]. Mothers with the oldest partners had 34% higher odds of gestational diabetes (1.34, 95% CI 1.29 to 1.38) [s2]. Higher paternal age was also associated with increased risk of low birth weight and low Apgar score [s2].

One number in that abstract deserves a caveat the abstract does not give it. The paper reports 18% higher odds of seizures, with an odds ratio of 1.18 and a 95% confidence interval of 0.97 to 1.44 [s2]. That interval includes 1, so the seizure finding is not statistically significant at the conventional threshold, and describing it as an increase overstates what the data show.

How much this matters at population scale

The cohort study answers that too, and the answer is the reason to keep the odds ratios in proportion. Of births to older fathers, an estimated 13.2% of premature births (95% CI 12.5% to 13.9%) and 18.2% of gestational diabetes cases (95% CI 17.5% to 18.9%) were attributable to advanced paternal age [s2].

The authors' own conclusion is that given the relatively low prevalence of advanced paternal age in the US, population-level impacts are currently modest — while noting that advanced paternal age has doubled in the US over the past generation, which is why they call for further investigation [s2].

That is an unusually clear statement of the difference between a relative risk and a public health problem. A 14% relative increase in preterm birth, applied to a small share of births, produces a small absolute effect on the national rate. It does not tell an individual couple much either way, because their absolute baseline risk is what determines what the multiplier does.

Where the clinical guidance sits

The AUA and American Society for Reproductive Medicine guideline on male infertility recommends that an initial infertility evaluation begin with concurrent assessment of both partners, rather than working through the female partner first, and that the male evaluation include a reproductive history and one or more semen analyses [s3]. It sets no paternal age threshold, and the evidence above is the reason: what the literature reports is a gradient in mutation counts and small shifts in birth outcomes, not a point at which something changes.

What is not established

Three things, and they are the ones people most want answered. There is no threshold age at which risk changes character; the studies above report gradients, not cut-points. There is no evidence here that any intervention reduces the mutation accumulation, because none of these studies tested one. And the step from "sperm carries more new mutations" to "this child will have a specific condition" is not made by any of this work — the mutation study measured mutations, and the perinatal study measured births, and neither followed children forward to see what happened.

This article is informational and is not medical advice.

Sources

• Rate of de novo mutations and the importance of father's age to disease risk — Nature, 2012-08-21
• Association of paternal age with perinatal outcomes between 2007 and 2016 in the United States: population based cohort study — The BMJ, 2018-10-31
• Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline (2024 amendment) — American Urological Association, 2024-08-15